News

Children’s National Research & Innovation Campus Welcomes New Resident Company, AlgometRx to JLABS

AlgometRx Inc., a Children’s National spinout company developing a handheld device to objectively measure pain by pupillary response, will relocate to Johnson & Johnson Innovation – JLABS @ Washington, DC on the Children’s National Research & Innovation Campus. The AlgometRx move comes following the company being awarded the JLABS @ Washington, DC Children’s QuickFire Challenge, which includes a one-year residency at the newly opened JLABS @ Washington, DC – a 32,000-square-foot incubator located at the new Children’s National Research & Innovation Campus in northwest Washington, D.C. As an awardee, AlgometRx also receives access to research and development space, capital equipment, mentorship, resources and programming.

Located on a nearly 12-acre portion of the former Walter Reed Army Medical Center campus, the Children’s National Research & Innovation Campus is the nation’s first campus dedicated to pediatrics, which formally opens in September 2021. This campus aims to help address a significant problem: the development of medical and surgical devices for children has long lagged behind that for adults. Over the past decade, only one in four medical devices approved by the Food and Drug Administration (FDA) were indicated for use in children, and the majority were for those ages 12 and up.

By bringing together public and private partners, the campus is a one-of-a-kind innovation ecosystem that aims to accelerate breakthrough discoveries into new treatments and technologies.

AlgometRx was founded by pediatric anesthesiologist Julia C. Finkel, M.D., and originated at the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National.

“Pain is the only vital sign that is not objectively measured,” Finkel said. “The current standard of measuring pain is the 0-10 scale, which is based on observations and subjective assessment. This technique increases the likelihood for inaccuracies, especially for infants and children who cannot clearly communicate their pain.”

Recent News

03/05/2025

Virginia Catalyst Awards $3.2 Million in Grants to Support Life Sciences in the Commonwealth

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $3.2 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These projects were awarded in Grant Round 17. “The Catalyst works to help industry partners and academic investigators to raise follow-on

02/27/2025

Hourigan Strengthens Leadership in Advanced Manufacturing and Data Centers with Key Appointments

Hourigan is expanding its leadership team to support the firm’s growing presence in two of the region’s most technical and high-demand industries: advanced manufacturing and data centers. Hourigan has named Mark Hourigan, Jr. to lead its advanced manufacturing and logistics sector and Mark Rainey to oversee its mission-critical and data center expansion. These appointments build

02/27/2025

The Estée Lauder Companies Partners with Serpin Pharma, Inc to Develop Breakthrough Skin Care Ingredients to Advance Longevity

The Estée Lauder Companies Inc. (NYSE: EL) (ELC)  announced a collaboration with biotechnology company, Serpin Pharma, that aims to explore how their anti-inflammatory research can be applied in cosmetics to deliver significant skin care longevity benefits to consumers around the world. The exclusive partnership will accelerate ELC’s focus on transformative product innovation by applying insights